Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 11/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 2/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21531002 | 1.00 | SMARCA2 (0.44) | SMARCA2SMARCA4PBRM1KRASPOLB | |
| SCHEMBL31745312 | 1.00 | SMARCA2 (0.44) | SMARCA2SMARCA4PBRM1KRASPOLB | |
| SCHEMBL21565913 | 0.90 | KRAS (0.45) | KRAS | |
| SCHEMBL21544302 | 0.90 | KRAS (0.45) | KRAS | |
| SCHEMBL29469059 | 0.90 | KRAS (0.45) | KRAS | |
| SCHEMBL21544300 | 0.90 | KRAS (0.45) | KRAS | |
| SCHEMBL21543731 | 0.89 | KRAS (0.42) | KRASGHSR | |
| SCHEMBL21531019 | 0.89 | KRAS (0.42) | KRASGHSR | |
| SCHEMBL26330291 | 0.89 | KRAS (0.39) | SMARCA2SMARCA4PBRM1KRASPOLB | |
| SCHEMBL21543750 | 0.87 | SMARCA2 (0.43) | SMARCA2SMARCA4PBRM1KRASMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3788053-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3790886-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3788053-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2019217691-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20190336514-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-20190336514-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.